The present review aims to describe the pharmacological aspects as well as the available clinical data supporting the choice of intracoronary route of administration for abciximab, an antiplatelet drug used in patients with acute coronary syndromes undergoing percutaneous coronary interventions (PCI). Abciximab is a glycoprotein (GP) IIb/IIIa receptor antagonist which determines a potent inhibition of platelet aggregation and thrombus formation. These properties seem to prevent not only thrombus formation but also to promote (at higher drug concentration) lysis of fresh thrombus. Moreover, differently from the other GP IIb/IIIa inhibitors, abciximab also binds to the vitronectin receptor on endothelial, smooth muscle, and inflammatory cells and to an activated conformation of the aMb2 receptor on leukocytes. Such cross-reactivity raises the possibility that clinical benefits derived from its use may not be exclusively due to its anti-thrombotic effect, but may also be related to the suppression of inflammatory pathways involving platelets, white blood cells, and the vascular endothelium. On such basis, the local administration of abciximab at the site of coronary thrombosis may enhance, by increasing its local concentration, the binding to both platelet and endothelium receptors. The results of several angiographic studies assessing the effect of intracoronary abciximab administration support on clinical grounds its adoption in patients with fresh coronary thrombosis. Indeed, better post-angioplasty coronary flow, greater degree of myocardial salvage and a better left ventricular function recovery have been achieved as compared to the intravenous, systemic, administration of drug's bolus.
Rationale for intracoronary administration of abciximab / Enrico, Romagnoli; Francesco, Burzotta; Carlo, Trani; BIONDI ZOCCAI, Giuseppe; Floriana, Giannico; Filippo, Crea. - In: JOURNAL OF THROMBOSIS AND THROMBOLYSIS. - ISSN 0929-5305. - 23:1(2007), pp. 57-63. [10.1007/s11239-006-9000-0]
Scheda prodotto non validato
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
|Titolo:||Rationale for intracoronary administration of abciximab|
|Data di pubblicazione:||2007|
|Citazione:||Rationale for intracoronary administration of abciximab / Enrico, Romagnoli; Francesco, Burzotta; Carlo, Trani; BIONDI ZOCCAI, Giuseppe; Floriana, Giannico; Filippo, Crea. - In: JOURNAL OF THROMBOSIS AND THROMBOLYSIS. - ISSN 0929-5305. - 23:1(2007), pp. 57-63. [10.1007/s11239-006-9000-0]|
|Appartiene alla tipologia:||01a Articolo in rivista|